DCOY

Decoy is a pre-clinical peptide-conjugate biotech with zero product revenue (last recorded revenue was $1.84M in FY2021; nothing since FY2022) and a five-year unbroken string of losses totaling into a -$94.4M accumulated deficit. FY2025 net loss was -$12.5M on a -212.6% ROE. This is not a business you value on fundamentals — there are none to value — it is a research option whose worth hinges entirely on unproven pipeline assets (the IMP³ACT platform, SP-3164, and seclidemstat/SP-2577) that the company itself describes as pre-clinical or being shopped for out-licensing (no further SP-2577 enrollment is planned).

The filing language turns a speculative story into an acutely dangerous one. The 10-K discloses a December 31, 2025 Nasdaq delisting determination for breaching the $1.00 minimum bid price, and — critically — the company was NOT eligible for the standard 180-day grace period because it had already executed the 2025 Reverse Stock Split and remains under a mandatory panel monitor. It was granted only until March 20, 2026 to comply. The current $7.31 price is a post-reverse-split artifact (shares outstanding collapsed to 532K, -69.5% YoY; diluted EPS of -$129.10 reflects that tiny share count), a classic sign of a company engineering its way to bare listing compliance rather than creating value. Serial reverse splits plus a panel monitor is a well-worn path toward eventual OTC/penny-stock relegation, which the filing spells out: reduced liquidity, loss of analyst coverage, and impaired ability to raise capital.